A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

ClinicalTrials.gov ID: NCT02717611

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02717611. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Study identification

NCT ID: NCT02717611
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Acerta Pharma BV; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Chronic Lymphocytic Leukemia

Interventions

ACP-196 (acalabrutinib) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 8, 2016 (Actual)
Primary completion: Oct 16, 2020 (Actual)
Completion: Jun 6, 2026 (Estimated)
Last update posted: Mar 25, 2026

2016 – 2026

United States locations

U.S. sites: 16
U.S. states: 10
U.S. cities: 15

Facility	City	State	ZIP	Site status
Research Site	Tucson	Arizona	85704	—
Research Site	Concord	California	94520	—
Research Site	La Jolla	California	92093	—
Research Site	Palo Alto	California	94304	—
Research Site	Washington D.C.	District of Columbia	20007	—
Research Site	Chicago	Illinois	60611	—
Research Site	Lake Success	New York	11042	—
Research Site	New York	New York	10021	—
Research Site	Columbus	Ohio	43210	—
Research Site	Nashville	Tennessee	37203	—
Research Site	Houston	Texas	77030	—
Research Site	Sherman	Texas	USA	—
Research Site	Seattle	Washington	98108	—
Research Site	Seattle	Washington	98122	—
Research Site	Spokane	Washington	99208	—
Research Site	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02717611, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 25, 2026 · Synced Nov 13, 2026